[1] Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis[J]. Am J Health Syst Pharm, 2019, 76(3): 130-135.
[2] Kalyanaraman H, Ramdani G, Joshua J, et al. A novel, direct NO donor regulates osteoblast and osteoclast functions and increases bone mass in ovariectomized mice[J]. J Bone Miner Res, 2017, 32(1): 46-59.
[3] Yuan FL, Ye JX, Wang HJ, et al. Effect of Yishen Mic Gu Recipe on bone coversion index betwa-CTX in patients with kidney deficiency osteoporosis[J/OL]. Journal of Clinical Medical Literature, 2017, 4(9): 17825-17827. (in Chinese)
袁凤来, 叶俊星, 王昊珏, 等. 益肾密骨方对肾虚型骨质疏松症患者骨转换指标β-CTX的影响[J/OL]. 临床医药文献电子杂志,2017,4(91): 17825-17827.
[4] Cao X. Targeting osteoclast-osteoblast communication[J]. Nat Med, 2011, 17(11): 1344-1346.
[5] Yuan FL, Ye JX, Li X. Effect of invigorating kidney and sealing bone recipe on bone formation in patients with kidney deficiency osteoporosis[J]. Chinese Journal of Osteoporosis, 2019, 25(8): 1163-1165, 1711. (in Chinese)
袁凤来, 叶俊星, 李霞. 益肾密骨方对肾虚型骨质疏松症患者骨形成的影响[J]. 中国骨质疏松杂志, 2019, 25(8): 1163-1165, 1171.
[6] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008, 83(9): 1032-1045.
[7] Tao H, Yang HY, Yu MCh, et al. Effects of systemic transplantation of allograft adipose-derived stem cells in glucocorticoid-induced osteoporosis rats[J]. Acta Anatomica Sinica, 2011, 42(20): 220-225. (in Chinese)
陶晖, 杨会营, 余美春, 等. 异体脂肪源干细胞移植对糖皮质激素性骨质疏松大鼠的影响[J]. 解剖学报, 2011, 42(2): 220-225.
[8] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation[J]. Nature, 2003, 423(6937): 337-342.
[9] Li C, Yang Z, Li Z, et al. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways[J]. J Bone Miner Res, 2011, 26(3): 644-656.
[10] Yuan FL, Xu RS, Ye JX, et al. Apoptotic bodies from endplate chondrocytes enhance the oxidative stress-induced mineralization by regulating PPi metabolism[J]. J Cell Mol Med, 2019, 23(5): 3665-3675.
[11] Liu D, Kou X, Chen C, et al. Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors[J]. Cell Res, 2018, 28(9): 918-933.
[12] Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D[J]. Nat Med, 2011, 17(11): 1473-1480.
[13] Sun W, Zhao C, Li Y, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity[J]. Cell Discov, 2016, 2: 16015.
[14] Li D, Liu J, Guo B, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation[J]. Nat Commun, 2016, 7: 10872.
[15] Barreca MM, Aliotta E, Geraci F. Extracellular vesicles in multiple sclerosis as possible biomarkers: dream or reality[J]. Adv Exp Med Biol, 2017, 958(1): 1-9.
[16] Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection[J]. Sci Signal, 2009, 2(100): ra81.
[17] Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function[J]. Trends Biochem Sci, 2012, 37(11): 460-465.
|